FDA Approves SODIUM BICARBONATE — Amneal Pharmaceuticals Private Limited

Amneal Pharmaceuticals Private Limited has secured FDA approval for its sodium bicarbonate injection, a generic version of Intravenous Sodium Bicarbonate (NDA220790), with the clearance effective as of July 9, 2026. This market expansion into the IV sodium bicarbonate segment is anticipated to intensify competition and potentially placate generic demand amidst methylene blue shortages.